AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...

AstraZeneca has announced data that it says will establish its lung cancer drug Tagrisso as standard second line treatment in patients with certain mutations. The data showed Tagrisso (osimertinib ...

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso ...

AstraZeneca (GB:AZN) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations. Now ...

Tagrisso (osimertinib) is a brand-name oral tablet that’s prescribed for certain adults with non-small cell lung cancer (NSCLC). The cost of the drug with and without insurance can depend on ...

(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso as treatment for a form of lung cancer.

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...